Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Kaul

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
Journal of the American College of Cardiology|June 15, 2019
Are Guidelines for Treatment of Hypertension Trustworthy?Sanjay Kaul
Annals of Internal Medicine|January 6, 2017
A Tale of Two Trials: Reconciling Differences in Results by Exploring Heterogeneous Treatment EffectsSanjay Kaul
The New England Journal of Medicine|August 15, 2019
Transcatheter Aortic-Valve Replacement in Low-Risk PatientsSanjay Kaul
The Canadian Journal of Cardiology|June 12, 2021
Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular MedicineSanjay Kaul
Hypertension (Dallas, Tex. : 1979)|September 21, 2020
Evidence for the Universal Blood Pressure Goal of <130/80 mm Hg Is Strong: Controversies in Hypertension - Con Side of the ArgumentSanjay Kaul
Journal of the American College of Cardiology|January 10, 2015
Choice of optimal anticoagulant to support primary PCI: out with the new, in with the oldSanjay Kaul
Circulation|July 13, 2016
Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?Sanjay Kaul
Journal of the American College of Cardiology|August 20, 2025
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into GuidelinesSanjay Kaul
Diabetes Care|January 10, 2018
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831Sanjay Kaul
Diabetes Care|November 23, 2017
Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831Sanjay Kaul
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Journal of the American College of Cardiology|June 15, 2019
Are Guidelines for Treatment of Hypertension Trustworthy?Sanjay Kaul
Annals of Internal Medicine|January 6, 2017
A Tale of Two Trials: Reconciling Differences in Results by Exploring Heterogeneous Treatment EffectsSanjay Kaul
The New England Journal of Medicine|August 15, 2019
Transcatheter Aortic-Valve Replacement in Low-Risk PatientsSanjay Kaul
The Canadian Journal of Cardiology|June 12, 2021
Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular MedicineSanjay Kaul
Hypertension (Dallas, Tex. : 1979)|September 21, 2020
Evidence for the Universal Blood Pressure Goal of <130/80 mm Hg Is Strong: Controversies in Hypertension - Con Side of the ArgumentSanjay Kaul
Journal of the American College of Cardiology|January 10, 2015
Choice of optimal anticoagulant to support primary PCI: out with the new, in with the oldSanjay Kaul
Circulation|July 13, 2016
Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?Sanjay Kaul
Journal of the American College of Cardiology|August 20, 2025
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into GuidelinesSanjay Kaul
Diabetes Care|January 10, 2018
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831Sanjay Kaul
Diabetes Care|November 23, 2017
Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831Sanjay Kaul
Pageof 19